The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.m

Sarcoid-like granulomatosis (endo-/extrathoracic)

Publications

Saito S, Shimizu M, Miyashita R, Inoue T, Nagano A, Kunugi S, Hatori T, Okano T, Seike M

Successful immunosuppressant-free treatment of a drug-induced sarcoidosis-like reaction caused by dupilumab.

Respiratory medicine case reports 2023;44;101883 — 2023 — 101883

Belhomme N, Gaignon T, Jouneau S, Misery L, Abasq-Thomas C, Cador B, Lecureur V, Cadiou S, Ballerie A, Polard E, Mensi S, Jego P, Lescoat A

Drug-induced granulomatosis: is dupilumab the new kid on the block?

Journal of the European Academy of Dermatology and Venereology : JEADV 2020 Jul;34;e312-e313 — 2020 Jul — e312-e313